Luxury boutique retailer Watches of Switzerland has reached a settlement in principle with Transport for NSW to resolve its case alleging damages resulting from Sydney’s light rail project, a court has heard.
A judge has gutted Buzzfeed’s truth defence in a defamation case brought by Labor MP Emma Husar accusing the news publisher of “slut shaming” her, saying the claims said to back the defence were “incapable” of supporting its case.
A judge has denied law firm Piper Alderman’s request to replace an uncooperative expert witness in a class action against KPMG over a failed takeover offer, three weeks before the matter goes to trial.
DLA Piper appears to have settled a case brought by a Queen’s Counsel alleging it skipped out on $274,000 in fees because the firm’s client had not paid its bill.
Maurice Blackburn has persuaded a judge to lift a temporary injunction that blocked the law firm from going ahead with plans to unveil a replica of the iconic New York statue, Fearless Girl, at Melbourne’s Federation Square for International Women’s Day.
Global insurer Jardine Lloyd Thompson has won access to the identities of local councils suing it in a NSW class action brought by Quinn Emanuel alleging the broker charged the councils excessive premiums.
Media organisations ABC and Fairfax have argued that a judge’s definition of espionage was “artificially narrow” when striking out their truth defence to a defamation case brought by Chinese philanthropist Dr Chau Chak Wing.
The Federal Government failed to read public submissions in approving a “flawed” assessment of a project supplying Adani’s controversial Carmichael coal mine with over 12.5 billion litres of water, an environmental group has told a court.
Gladstone Ports has won access to draft expert reports prepared by Clyde & Co in its $100 million class action against the Queensland government owned organisation, with a judge ruling the documents were not privileged despite their not being used in the case.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.